Voyager Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Voyager Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $65.30 million for the year ending 2025.

  • Voyager Therapeutics, Inc. showed a decrease of -8.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 13 years of available data (2013 to 2025), Voyager Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 48,270.4%.
  • Historical annual values: Fiscal year 2025: $65.30 million | Fiscal year 2024: $71.37 million | Fiscal year 2023: $68.80 million | Fiscal year 2022: $98.96 million | Fiscal year 2021: $117.43 million | Fiscal year 2020: $104.44 million | Fiscal year 2019: $86.04 million | Fiscal year 2018: $46.86 million | Fiscal year 2017: $31.53 million | Fiscal year 2016: $36.64 million | Fiscal year 2015: $31.31 million | Fiscal year 2014: $7.04 million | Fiscal year 2013: $135.0 thousand.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: